TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04301479
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal
Study: NCT02947178
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02947178
Drug: Liposomal Bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01474772
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150-300 mg/day given in 3 divided doses as capsules
Study: NCT01637636
Drug: tasimelteon
Normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg, oral capsule, once, Days 1 and 12
Study: NCT01637636
Drug: tasimelteon
Normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg, oral capsule, once, Days 1 and 6
Study: NCT01637636
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
Study: NCT01637636
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6
Study: NCT00788099
Drug: Plitidepsin and Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
Study: NCT00788099
Drug: Gemcitabine and Plitidepsin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
Study: NCT00839449
Drug: Eicosapentaenoic acid ethyl ester
Normalized name: Eicosapentaenoic acid ethyl ester
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
Study: NCT01165320
Drug: Caspofungin
Normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00134654
Drug: Premarin
Normalized name: Premarin
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
Study: NCT00054951
Drug: MTC-DOX for Injection
Normalized name: MTC-DOX for Injection
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00445107
Drug: MK0476, montelukast sodium / Duration of Treatment: 8 Weeks
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01229254
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients on Amiodarone
Study: NCT02224235
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
Study: NCT01229254
Drug: Betrixaban 60 mg
Normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betrixaban 60 mg once a day with food on Day 0 through Day 25
Study: NCT01229254
Drug: Betrixaban 90 mg
Normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betrixaban 90 mg once a day with food on Day 0 through Day 25
Study: NCT01229254
Drug: Betrixaban 30 mg
Normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
Study: NCT02224235
Drug: DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the discretion of the investigator as to which DAPT is administered (per local practice)
Study: NCT03656965
Drug: Acyclovir 800 MG
Normalized name: acyclovir 800 MG
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir tablets 800 mg per day during the whole course of treatment Or Placebo.
Study: NCT01923363
Drug: Piperacillin/Tazobactam Standard Dose to High Dose
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
Study: NCT03619707
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
Study: NCT00834990
Drug: divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: delayed-release 500 mg tablet
Study: NCT00988364
Drug: Vytorin
Normalized name: Vytorin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vytorin 20/10mg daily for 3 months.
Study: NCT00988364
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe 10mg daily for 3 months.
Study: NCT03295383
Drug: Rituximab 1g IV
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab at a dose of 1000 mg will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197
Study: NCT03295383
Drug: Placebo of Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab placebo will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab administration on Day 182 and Day 197
Study: NCT00003914
Drug: dolastatin 10
Normalized name: Dolastatin 10
DrugBank: Dolastatin 10 (DB12730)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01235923
Drug: weekly Epo
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks
Study: NCT00521599
Drug: Mometasone furoate dry powder inhaler
Normalized name: mometasone furoate Dry Powder Inhaler
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02624063
Drug: Daclatasvir + Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks
Study: NCT02624063
Drug: Simeprevir + Sofosbuvir
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks
Study: NCT00005901
Drug: Pamidronate (Aredia)
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
Study: NCT00460278
Drug: XL418
Normalized name: XL418
DrugBank: XL418 (DB05204)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00804687
Drug: JNJ-39220675
Normalized name: JNJ-39220675
DrugBank: JNJ-39220675 (DB12929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.
Study: NCT00804687
Drug: Pseudoephedrine
Normalized name: Pseudoephedrine
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.
Study: NCT01748526
Drug: Canagliflozin (JNJ-28431754) 200 mg
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 200 mg tablet taken orally (by mouth) on Day 1.
Study: NCT01748526
Drug: Canagliflozin (JNJ-28431754) 300 mg
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 300 mg tablet taken orally (by mouth) on Day 1.
Study: NCT00515294
Drug: Caffeinated Alcoholic Beer
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic Beer plus Caffeine Citrate powder.
Study: NCT00515294
Drug: Caffeinated Non-Alcoholic Beer
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-Alcoholic Beer plus Caffeine Citrate powder.
Study: NCT01610713
Drug: GW-1000-02
Normalized name: GW-559090
DrugBank: GW-559090 (DB06508)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
Study: NCT03349424
Drug: Somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin (Stilamin®) of 250μg/h, beginning within 3 hours (Visit 1) after the operation and lasting for 120 hours (each subject will receive the Stilamin of 30mg in total), and other postoperative conventional treatment protocol remain unchanged.
Study: NCT02471560
Drug: dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As per the prevailing local label.
Study: NCT02471560
Drug: injectable MS DMT
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As described above.
Study: NCT02312804
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
Study: NCT03585036
Drug: dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
Study: NCT03585036
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure
Study: NCT00531557
Drug: Darunavir ritonavir
Normalized name: Darunavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02312804
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
Study: NCT00004495
Drug: cyanocobalamin
Normalized name: Cyanocobalamin
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02479165
Drug: Ibuprofene
Normalized name: Ibuprofene
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.
Study: NCT02479165
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The opioid group is given an oxycodone based analgesic regimen.
Study: NCT02382029
Drug: Clonazepam
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active medical treatment for burning mouth syndrome
Study: NCT01572363
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg once
Study: NCT03061721
Drug: Saroglitazar magnesium 1 mg
Normalized name: pitavastatin magnesium 1 MG
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
Study: NCT03061721
Drug: Saroglitazar magnesium 2 mg
Normalized name: pitavastatin magnesium 2 MG
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
Study: NCT03061721
Drug: Saroglitazar magnesium 4 mg
Normalized name: pitavastatin magnesium 4 MG
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
Study: NCT03447314
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
Study: NCT01124123
Drug: Bilastine
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 20 mg oral tablet
Study: NCT01124123
Drug: Bilastine
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 10 mg endovenous bilastine
Study: NCT01534260
Drug: sorafenib, vorinostat and bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
Study: NCT00434083
Drug: sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00309699
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
Study: NCT00309699
Drug: Paliperidone ER
Normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 to 12 mg daily, flexibly dosed, for 12 weeks
Study: NCT00683917
Drug: Proellex 25 mg
Normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
DrugBank: Telapristone acetate (DB05253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proellex 25 mg, 1 capsule daily for 4 months
Study: NCT00683917
Drug: Proellex 50 mg
Normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
DrugBank: Telapristone acetate (DB05253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proellex 50 mg, 2 capsules daily for 4 months
Study: NCT00683917
Drug: Lupron Depot
Normalized name: Lupron Depot
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupron 3.75 mg monthly intramuscular injections for 4 months
Study: NCT00123578
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam
Study: NCT00123578
Drug: Pentobarbital
Normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentobarbital
Study: NCT00144248
Drug: nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04319380
Drug: SMC with SP+AQ
Normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Year 1 and 2 (2020/21) Four cycles of SMC (SP+AQ) (July, August, September, October). One cycle of SMC consisting of sulphadoxine - pyrimethamine (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3.
Study: NCT01524991
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2 Days 1 \& 8 (all cycles)
Study: NCT01524991
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 70 mg/m2 Day 1 (all cycles)
Study: NCT01524991
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg Day 1 (start cycle 3)
Study: NCT04611425
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours. The dose of Remimazolam will be adapted according to the ICU units protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale). Owing to previous data gathered through a previous study in Japan, the initial dose of infusion will be within a 0.2-0.5 mg/min range. The dose of Remimazolam can be increased or decreased by 0.1mg/min when needed. The maximum dose of Remimazolam will be set at 1 mg/min.
Study: NCT06607393
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06607393
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06607393
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06607393
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000293
Drug: Nefazodone
Normalized name: Nefazodone
DrugBank: Nefazodone (DB01149)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02666651
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.
Study: NCT01713283
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT00350272
Drug: Elvucitabine
Normalized name: Elvucitabine
DrugBank: Elvucitabine (DB06236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elvucitabine 10 mg orally daily
Study: NCT00350272
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine 300 mg orally daily
Study: NCT00350272
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir open-label 300 mg orally daily
Study: NCT00350272
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenze open-label 600 mg orally daily
Study: NCT00812006
Drug: rizatriptan benzoate
Normalized name: Rizatriptan Benzoate
DrugBank: Rizatriptan (DB00953)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack
Study: NCT03908372
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction CT: Docetaxel 75mg/m2 IV on d1, every 21 days for two cycles
Study: NCT03908372
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction chemotherapy:cisplatin 75mg/m2 IV on d1,every 21 days for two cycles.Concurrent chemoradiotherapy:cisplatin 100mg/m2 IV on d1 of each 21 days for at least two cycles during 70 Gy radiotherapy
Study: NCT02017392
Drug: Compound Lidocaine Cream
Normalized name: BENZOIN COMPOUND
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compound Lidocaine Cream ,1-2 grams per person.
Study: NCT00937144
Drug: Viagra (Sildenafil)
Normalized name: sildenafil Oral Tablet [Viagra]
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Viagra treatment to patients with sickle cell anemia.
Study: NCT02478840
Drug: Lamazym
Normalized name: Lamazym
DrugBank: Velmanase alfa (DB12374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant human alpha-mannosidase
Study: NCT01571050
Drug: Purified water
Normalized name: Purified water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 30 mL of purified water
Study: NCT01607333
Drug: Lamotrigine use
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine prescription during the study period
Study: NCT03496233
Drug: Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]
Normalized name: elbasvir 50 MG / grazoprevir 100 MG Oral Tablet [Zepatier]
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with EBR/GZR Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients, with non- severe fibrosis, with or without IR and/or DM
Study: NCT02629848
Drug: Motesanib
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib (AMG 706) 5 x 25 mg tablets
Study: NCT02629848
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel IV
Study: NCT02629848
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin IV
Study: NCT00845039
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m² every 14 days until disease progression or participant intolerance